Clinical Trial

Maintenance Electroconvulsive Therapy (ECT) Versus Aripiprazole in Clozapine-resistant Schizophrenia

Unknown Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated July 16, 2024 (before its estimated October 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The pharmacological treatment options in schizophrenia developing resistance to clozapine are limited. Few studies have found ECT as beneficial in TRS, including CRS. However, literature on the role of M-ECT in maintaining the therapeutic gains of acute ECT in CRS is lacking. The objective of the study is to compare the efficacy of M-ECT vs aripiprazole as an add-on to ongoing clozapine on the severity of symptom dimensions, cerebral perfusion, global functioning and cognitions in patients with CRS.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06501339
Lead Sponsor All India Institute of Medical Sciences, Bhubaneswar
Conditions Clozapine Resistant Schizophrenia
Enrollment 40 participants
Start Date 2024-08-10
Primary Completion 2025-10-31 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-16